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1. Introduction 
Low density lipoproteins (LDLs) are the principal transporter of cholesterol and fat in 
human blood. Circulating LDLs guarantee a constant supply of cholesterol for tissues and 
cells, whereas cholesterol is required for membrane synthesis, modulation of membrane 
fluidity and the regulation of cell signaling pathways. The function of LDL in metabolism 
is mediating by cellular uptake via receptor-mediated endocytosis followed by lysosomal 
degradation [1,2], and is strongly dependent on the lipid distribution, the structure of 
LDL particles and on the proper conformational orientation of apolipoprotein B100 (apo-
B100). Apo-B100 is the sole protein component of LDL being mainly located on the surface 
of LDL. Apart from their well established role as lipid transporter, LDL particles are 
intimately involved in the progression of cardiovascular diseases such as atherosclerosis 
or stroke, which are among the most prevalent causes of death in developed countries [3]. 
In particular, raised plasma levels of LDL are linked to an increased risk for disease. 
Moreover, dysregulations of LDL due to abnormalities in LDL structure have been 
identified as independent predictors of risk for coronary heart diseases [4,5]. LDL 
particles by themselves are highly heterogeneous in nature, varying in their buoyant 
densities, size, surface charge and chemical composition [6,7], and these biochemical 
characteristics determine the fate of LDL in the subendothelial space [8,9]. For example, 
small, dense LDL subclasses are more atherogenic than their light counterparts, which are 
more susceptible to modifications [5,10]. Modifications of LDL, primarily through 
oxidation, enzymatic degradation or lipolysis are the initiating factors in early 
atherosclerosis. In that case, LDL particles accumulate in the intima of the arterial wall 
where apo-B100 binds to proteoglycans of the extracellular matrix through ionic 
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interactions. As a consequence, LDL becomes trapped in the subendothelium, where it is 
prone to oxidation processes, aggregation and fusion. Bioactive lipids, such as oxidized 
phospholipids, lysolipids or oxidized cholesterylester, are released from LDL particles, 
which are simultaneously non-specifically altered. A broad spectrum of diverse LDL 
particles with non-defined physicochemical properties is generated that, in turn, promotes 
a rapid uptake of these particles by macrophages to form foam cells [11]. This is one of the 
key steps in the progression of atherosclerosis. Today, atherosclerosis is known to be a 
chronic inflammatory disorder of the blood vessels and recognized as a prevailing cause 
of cardiovascular disorders, the leading causes of morbidity and mortality worldwide 
[12]. Since the early initiation of atherosclerosis strongly depends on the metabolism of 
LDL, which is predominantly triggered by molecular characteristics of LDL, it is of 
paramount biomedical importance to explore structural features of LDL particles in great 
detail. However, mostly due to the complex nature of LDL particles many questions 
concerning molecular details are still unanswered.  
This article will review our current knowledge on the structure and dynamics of LDL 
particles. In fact, several recent studies revealed that the molecular organisation and 
dynamics of LDL core lipids, in close relationship to the intrinsic dynamics of LDL surface 
components, control not only the metabolism of lipids in humans, but determine the role 
of LDL in the pathogenesis of cardiovascular diseases. In this article, we will give a short 
historical review on LDL structure and then present prevailing concepts on the self-
organisation of LDL. Special emphasis will be paid to dynamic features of LDL particles. 
In particular, we will discuss the interplay between structure and dynamics in more 
detail. Finally, we will give an outlook to promising future strategies to clarify the 
molecular structural details of LDL and how to exploit LDL nanoparticles for medical 
needs.  
2. Molecular architecture of LDL 
LDLs are composed of lipids and protein, which assemble to form a supramolecular 
complex with a molecular mass exceeding 2.5 - 3.0 million Da and involving 2000 to 3000 
lipid molecules. Thus, LDL particles are commonly described as micellar complexes, 
macromolecular assemblies, self-organized nanoparticles or microemulsions. Regardless of 
diverse definitions, it is generally accepted that assembled LDL particles are organized into 
two major compartments, namely an apolar core, comprised primarily of cholesteryl esters 
(CE), minor amounts of triglycerides (TG) and some free unesterified cholesterol (FC). The 
core is surrounded by an amphipathic outer shell. This shell is composed of a phospholipid 
(PL) monolayer containing the larger part (>2/3) of the FC molecules and one single copy of 
apo-B100, which is one of the largest known monomeric glycoproteins [13]. Figure 1 
provides an overview on characteristic properties of LDL together with a schematic 
presentation of an LDL particle. Since molecular interactions between different kinds of 
lipids have turned out to be highly complex, it is almost impossible to separate the surface 
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and core regions exactly from each other. Accordingly, in some recent reports an additional 
hydrophobic interfacial layer composed of phospholipid acyl chains, FC, some CE 
molecules and hydrophobic protein domains is defined. This description takes account for 
the interplay between neutral core lipids and the surface layer [14]. 
 
 
 
Figure 1. Molecular organisation of LDL. LDL particles are isolated from human plasma within a 
defined density range. Their particle size varies between 20 to 25 nm. LDLs are built up by a 
hydrophobic lipid core of cholesterylester (CE) and triglyceride (TG) molecules, which make up more 
than 40% of particle mass surrounded by a phospholipid (PL) monolayer corresponding to about 20% 
of particle mass. Varying amounts of free cholesterol (FC) are incorporated in the shell and the core 
regions. One single copy of apo-B100 (550 kDa) is embedded in the surface monolayer, partially 
penetrating the core and covering about 40 to 60% of the surface area. The carbohydrate moieties are 
distributed along the protein chain and are surface exposed. The N-terminal end of apo-B100 (about 
26% of total) is hydrophilic and shows a high homology to lamprey lipovitellin. The C-terminal end was 
shown to be located close to the N-terminus.  
Since LDL particles are highly heterogeneous, especially with respect to the chemical 
composition of the core lipids, the actual size of LDL particles varies between 20 to 25 nm, 
with an average particle diameter of about 22 nm. This intrinsic heterogeneity allows a 
subdivision of LDLs into distinct highly homogeneous LDL subspecies, which are 
identified on the basis of their hydrated densities, which normally lies between the 
extremes of d, 1.019 and 1.063 g ml-1 [15]. These subspecies also differ in their physico-
chemical characteristics, receptor binding affinity [16], susceptibility to oxidative 
modifications [17,18], and in their atherogenic behaviour. Following these lines, it is 
important to consider LDL as a flexible construct, which needs to respond to changing 
environmental conditions during lipid exchange. Hence, during particle remodelling, apo-
B100 and the surface PL molecules have to rearrange to compensate for changes in the 
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surface area and surface pressure [6]. It is known, that apo-B100 predominantly resides on 
the surface of LDL and displaces PL molecules, concomitantly changing the diffusion and 
order parameter of lipids as shown in a recent near atomistic simulation study [19]. Based 
on simple geometrical considerations taking into account the surface PL monolayer (about 
700 PL molecules) with an average area per lipid of 0.65 nm2 and an LDL particle 
diameter of 22 nm, large parts of the surface layer must be covered by the protein to avoid 
unfavourable hydrophobic contacts. In support of these considerations, a loose surface 
packing of PL molecules was derived from molecular dynamics simulations [19]. This low 
surface pressure enables hydrophobic amino acid regions of apo-B100 to penetrate into 
the interfacial regions, predominantly formed by the acyl chains of PLs. Consequently, 
apo-B100 might interact more readily with the neutral core lipids, and indeed it was 
shown that some of the CE molecules align along the β-sheet structures of apo-B100 [20], 
thereby driving CE molecules to the surface, where they become part of the interfacial 
layer. Particularly noteworthy is the fact that the lipids within the interfacial layer are not 
homogeneously distributed but form local microenvironments [14]. More precisely, two 
nanodomains were identified, one rich on sphingomyelin and FC, the other one rich in 
phosphatidylcholine and poor in FC. The latter was shown to be associated more closely 
with apo-B100 [21]. Even though, one has to keep in mind that these domains are not 
static or confined in size and number and co-determine the intrinsic dynamics of LDL. 
Based on these types of findings, it seems reasonable to suggest that variations in the 
molecular organisation of lipid/apo-B100 impact the structure of LDL, and have to be 
considered to act as physiological determinants of LDL function. 
3. Structural models of LDL 
Our present understanding of the structure of LDL particles has emerged from the 
concerted application of different physico-chemical techniques with early ground-breaking 
findings derived from neutron- or X-ray small angle scattering data [22-25] complemented 
by results from negative staining electron micoscopic (e.m.) [26,27] and spectroscopic 
techniques [28,29]. For comprehensive reviews on different biophysical studies applied on 
LDL species see refs. [30,31]. In recent years structural investigations using cryo-e.m. 
reconstruction techniques have become prevalent and with time 3-dimensional models with 
improved resolution were presented [32-37]. While in earlier studies LDLs are described as 
quasi-spherical particles, later studies presented a new view of the overall particle structure 
displaying an oblate elliptical particle shape. Moreover, recent 3D-images show convincing 
data that LDL can be considered as discoidal-shaped particle with two flat surfaces on 
opposite sides. In this model, apo B100 encircles LDL at the edge of the particle, while the 
PL monolayer is rather located at the flat surfaces which are parallel to the CE layers in the 
core [36,37]. To get a better impression of what LDL looks like in a structure map obtained 
by 3D-reconstruction from cryo-e.m, we show some images in Figure 2 revealing the surface 
density distribution on LDL. It has to be stated that this model strictly holds true for LDL 
particles with the core lipids being in a frozen liquid-crystalline state. 
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Figure 2. Density distribution at the surface of LDL. The 3D-density map derived from cryo e.m. 
images by reconstitution reveals the oblate overall particle shape of LDL shown in gray. The overlaid 
high density regions represent the backbone of apo-B100, colored in orange. The belt surrounds the 
particle to form an enclosed circle. The second group of high density regions (green) contours the rims 
and complements the backbone enclosing lower-density regions. The high density regions on the 
sidewall (yellow) are structures extending from the backbone. A knob-like protrusion is visible at the 
pointed end (indicated by triangles in the right and top views). The 3D-map is turned 90° in each frame. 
Reprinted with permission from ref. [37]. 
4. Core lipid packing and lipid phase transition  
Despite of compositional heterogeneity, LDL particles share one common feature: the CE 
molecules in the core undergo a structural transition from an ordered liquid-crystalline phase 
to a fluid oil-like state as function of temperature and chemical composition [38]. More 
precisely, the actual transition temperature, which is close to body temperature, is inversely 
correlated to the content of triglycerides within the lipid core [22,39]. Based on these 
characteristics, several models for CE packing have been suggested including a spherical 
concentric layer model derived primarily from X-ray and neutron scattering data [40,41]. More 
recently, the concept of a flat lamellar structure came up. This model is derived from single-
particle reconstructions from cryo-e.m. images of LDL in vitreous ice [32,34]. An ordered 
three-layer internal lamellar structure with a distance of about 3.6. nm between the single 
lamellae was reported [32], in agreement with repeat distances derived from X-ray scattering 
patterns for LDL below the transition temperature. While these images were observed for LDL 
particles being in the liquid crystalline phase before snap-freezing, diverse results were 
reported for LDL particles frozen from a state above the phase transition temperature [42,43]. 
One plausible explanation for these discrepancies might be that the melting rate of the core 
lipids proceeds extremely fast. It has been shown that the physical state of core lipids changes 
within milliseconds [44]. This fast kinetics has caused experimental difficulties for long time, 
however, a recent experimental approach by speeding up freezing allowed to trap the lipids in 
the molten state [45]. The authors report on a co-existing phase of layered and broken shells for 
LDL particles, which are shock-frozen in a state above the phase transition. This is the first 
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time to visualize the nucleation process of CEs within LDL. Most interesting, the images 
indicate intermediate states between the order/disorder phase transition. Figure 3 shows the 
dynamic model of the core CE packing during the phase transition and gives a comparison of 
the internal features of reconstructed 3D-volumes of LDL.  
 
Figure 3. Schematic picture of the dynamic model of LDL core lipid packing during the phase 
transition. Comparision of the internal features of the reconstructed 3D-volume of LDL snap-frozen 
from below (22°C) and above (53°C) the phase transition temperature (Tm). Samples prepared from 
22°C show a layered organisation while samples prepared from 53°C reveal a disorded shell like 
structure, which is concentric to the surface. Note, the overall shape of LDL has also changed slightly. 
The lower panel shows a hypothetical model for the core lipid packing depicting the dynamic process 
of the core lipid phase transition upon cooling from isotropic to layered passing through an 
intermediate state. Modified with permission from ref. [45].  
In summary, it seems reasonable to argue that both the overall shape and core lipid packing 
of LDL particles are highly sensitive to changes in temperature and lipid composition. 
Indeed, this newly proposed patch nucleation behavior permits the temporary formation of 
local molecular microenvironments as suggested previously by our group in terms of 
trigylceride segregation [46]. In the next paragraph we will address some interesting 
questions in support of above hypotheses. 
Does a lipid microphase separation occur in LDL particles as a function of the relative core 
content of CE and TG ? 
As already mentioned, the transition temperature correlates with the lipid composition, 
however, a discontinuity in the concentration dependence was observed [46]. A break in the 
concentration dependence of a transition temperature in a mixed lipid system constitutes an 
index for the existence of a phase separation at the break point. In isolated triglyceride - 
cholesteryl ester systems no indication of a phase separation at similar compositions was 
found [39,47]. It appears therefore, that structural constraints within the LDL particle 
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determine this effect. Experimental data provide evidence that at low TG content (below 
12%) the TG molecules separate into distinct hydrophobic nanoenvironments while the CEs 
form a smectic liquid crystalline layer. With increasing TG content the thermal stability of 
the CE layer is decreased by intermixing with TG [46]. This hypothesis implies that the TG-
rich fluid nanodomains can serve as a reservoir for lipophilic minor constituents, such as 
vitamins (tocopherol, carotenoids etc.) below the phase transition. The local concentration of 
these antioxidants and hence their efficiency in scavenging lipophilic free radicals is higher 
than if they were dissolved in the bulk volume of total apolar lipids. At the same conditions 
the CE molecules are strongly immobilized and the intracellular degradation of LDL is 
decelerated [48], equally the activity of lipid transfer proteins is diminished [49,50]. Based on 
these considerations it is tempting to speculate that circulating LDL, as a consequence of the 
variation in blood temperature, periodically undergoes a thermal transition resulting in a 
transient increase in the local core concentration of minor constituents [46]. Here, it should 
be emphasized that a periodic redistribution of lipophilic solutes, and also for example of 
drugs, into the confined LDL core volume could represent an attractive approach to the 
modulation of biochemical reactions, which would not occur at sufficient rates under the 
normal conditions of relative concentration. Studies along these lines could indeed verify 
the long missing physiological role of the thermal LDL transition. 
Can LDL structure follow quasi-isothermal changes in blood temperature during its 
circulation, or does it remain adiabatically metastable in the molten-lipid state?  
In order to provide evidence to answer this question we have applied time resolved X-ray 
scattering experiments using a high flux synchrotron generated X-ray beam. Thus, we have 
been able to trigger the thermal transition in either direction (heating and cooling) 
simultaneously monitoring associated structural changes in sub-second time intervals. With 
our special instrumental setup we managed to evaluate the kinetics of core-transition by T-
jump and T-drop experiments [44]. We found that the melting transition proceeds faster 
than 10 milliseconds indicating that thermal-induced lipid reorganisation takes place at the 
time scale of blood circulation. As the velocity of blood-flow can be as low as 0.3 mm/s in 
peripheral blood capillaries the residence time for LDL particles in cooler regions of the 
body can be several seconds. Consequently, LDL can easily follow periodic temperature 
changes during blood circulation and assist the redistribution of lipophilic constituents 
within its core nanodomains forming fluid defect zones. For biomedicine, this strengthens 
the hypothesis that the core lipids of LDL not only act as passive chemical substrates in 
metabolism, but that their physical state within the LDL nanoparticles has the potential to 
control their metabolic fate in normal and atherosclerotic cholesterol transport. 
Does the core lipid transition have a physiological meaning ? 
Despite its occurrence conspicuously close to blood temperature and the variation of the 
transition temperature of LDL among different subjects, no clear evidence for a 
physiological or patho-biochemical role of this transition has so far been found. It is now 
generally accepted in literature that the rearrangement of the core lipids also affects the 
overall structure and shape of the LDL particle. Morphological changes in turn can impact 
receptor-binding activity as well as the action of lipid hydrolyzing enzymes. Equally, the 
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susceptibility of LDL particles to oxidative modifications and lipid peroxidation might be 
correlated to temperature [18]. As oxidized LDL play a crucial role in the pathogenesis of 
atherosclerosis, any contribution to the comprehension of antioxidant efficiency may be of 
therapeutic potential [2,51], further pointing to the physiological relevance of the lipid core 
organisation. However, this vital question still remains unanswered.  
5. Apo-B100 is a flexible string wrapped around the surface of LDL 
As already indicated above, the physicochemical state of the core lipids is intimately related to 
the structure and dynamics of the particle surface, which consists of about 700 phospholipid 
molecules and one single copy of apo-B100. Apo-B100 is a huge glycoprotein and its 
polypeptide chain consists of 4536 amino acid residues with an estimated molecular mass of 
about 550 kDa for the glycosilated form [52,53]. Apo-B100 is a single chain protein with a total 
contour length of about 70 nm [54] and can be viewed as a highly flexible molecular string 
composed of single domains [20]. Five consecutive domains were identified based on 
secondary structure elements representing the main conformational motifs of apo-B100. The 
single domains are connected by flexible interdomain linker regions, which allow relative 
movements of domains to each other. The feasibility of such motions was shown in a low 
resolution model of detergent solubilized apo-B100, which was derived from small angle 
neutron scattering data [55]. In this model, compact rigid domains are visible being connected 
by flexible interdomain linkages, which possess a substantial degree of freedom in their spatial 
orientation. A hypothetical spatial arrangement of the apo-B100 molecule on a spherical LDL 
particle was created after assigning the secondary structure elements, which were deduced 
from a secondary structure prediction, to the surface of apo-B100 (Figure 4). Likewise, the 
averaged surface shape of the 3D-model would allow for variations in the thickness of the apo-
B100 molecule by about 1 nm. Such variations are most likely required to compensate for 
changes in the surface area upon lipid exchange and particle shrinking during endogeneous 
lipoprotein conversion from very low density lipoprotein (VLDL) to LDL.  
 
Figure 4. Reconstituted low resolution model of lipid-free apo-B100 derived from small angle neutron 
scattering data. Apo-B100 shows an elongated arch-like morphology indicating single domains and 
mobile less defined linker regions. A hypothetical model of a spherical LDL particle after superposition 
of the structural model of apo-B100 is shown (adapted from ref. [55]). Secondary structure modules are 
assigned to the surface after a secondary structure prediction was performed. The results nicely 
correspond to the pentapartite model suggested by [20].  
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Concerning the topology of apo-B100 on the surface of LDL the most detailed information is 
obtained from cryo-e.m. images (see also Figure 2). Chatterton et al. were among the first to 
visualize apo-B100 as string circumventing LDL, and to report on mapped epitopes of apo-
B100 distributed over one hemisphere of the LDL particle [56,57]. Recent single particle 3D-
reconstructions from immuno cryo e.m. images delineated a more accurate picture of apo-
B100 revealing a looped topology of the protein backbone with distinct epitopes identified 
along the protein chain. According to this model, epitopes in the LDL receptor binding 
domain are located on one side of LDL, whereas epitopes located in the N-terminal and C-
terminal domains are in close vicinity to each other on the opposite side of LDL [36]. In 
addition, a prominent protrusion is visible in the images at the pointed end of the particle. A 
similar knob-like region was apparent in the low resolution model of lipid-free apo-B100 
shown in Figure 4. This protrusion most probable represents the non-lipid associated 
globular N-terminal domain of apo-B100, which shows a high homology to lamprey 
lipovitellin [58]. Except for the N-terminal domain, little is known about the molecular 
organisation of the structural motifs, whose amphipathic nature determine lipid association. 
However, to evaluate lipid-protein interactions physical parameter like interfacial elasticity 
or molecular dynamics have to be considered. In this context, it was suggested that the 
hydrophobic β-sheet domains of apo-B100 act as elastic lipid anchors, whereas the 
amphipathic α-helical domains respond rapidly to changes in surface pressure [59,60]. In 
any case, it can be assumed that alterations in the adsorption and penetration depth of apo-
B100 in the phospholipid monolayer and in the lipid core are accompanied by structural 
rearrangements of the domains and changes in the orientation of the domains relative to 
each other. In the course of such elastic motions, intramolecular rearrangements are likely to 
alter the overall hydrophobicity and surface activity of single protein domains. These 
modifications not only affect lipid-protein interaction, but are equally important for 
molecular and cellular recognition of apo-B100. 
6. Apo-B100 containing lipoproteins are very soft and flexible 
LDL particles are formed in the circulation by lipolytic conversion of TG-rich VLDL 
particles. This enzyme mediated endogenous transformation is accompanied by an 
extensive shrinking in particle size from about 50-80 nm for VLDL to ~20 nm for LDL. In the 
course of remodelling, apo-B100 remains bound to its nanocarrier stabilizing the lipid 
assembly by maintaining structural integrity. To accomplish this, apoB100 has to become 
more condensed or relaxed depending on the lipid packing density. Likewise, this dynamic 
process is modulated by the molecular mobility of the surrounding microenvironment. To 
test for this hypothesis we have recorded temperature dependent molecular motions in 
VLDL and LDL particles using elastic incoherent neutron scattering [61]. With this 
technique, motions in the nano- to picosecond time scale can be recorded. The calculated 
dynamic force constants are a direct measure for the resilience of the particles. The results 
show that at physiological temperatures VLDL particles are very soft, elastic and mobile as 
compared to LDL, which is more rigid (see Figure 5). This observation supports the notion 
that apo-B100 in VLDL is loosely packed at the interface covering a large surface area with 
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low interfacial surface tension [59]. During particle conversion from VLDL to LDL, however, 
the relative number of surface molecules increases and a higher molecular packing density 
leads to a compression of the lipid anchored protein regions and an overall stiffening of the 
LDL particle [60].  
 
Figure 5. Molecular motions in LDL and VLDL. Elastic temperature scans are recorded with elastic 
incoherent neutron scattering. The mean square thermal fluctuations (<u2>) are shown as function of 
temperature. The molecular resiliences are derived from the slopes in the curves. It is seen that VLDL 
has an increased motion at elevated temperatures compared to LDL. Parts of this figure are reproduced, 
with permission, from ref. [60]. 
To conclude, the intrinsic conformational flexibility and elasticity of apo-B100 containing 
lipoprotein particles is most likely critical for specific affinities of lipoproteins to receptors, 
antibodies or enzymes. Moreover, it would seem that the susceptibility of lipoproteins to 
oxidative modifications and hence their atherogenicity is influenced by their dynamic 
nature. 
7. LDLs are flexible nanotransporters circulating in blood  
In the search for new and improved therapeutics, the field of nanomedicine dealing with 
functionalized nanoparticles for molecular imaging and therapy is rapidly emerging. 
Nanoparticles offer new opportunities to transfer active substances directly to the diseased 
site in the body. By additional surface coatings or functionalizations, the properties of 
nanoparticles can be tuned to specific needs. Within the last two decades, a variety of 
artificial nanoparticles have been designed for targeted delivery of drugs or contrast agents. 
Many of these nanoconstructs are developed for cancer therapy taking advantage of the  
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leaky vasculature of tumours. Apart from tumour targeting, increasing efforts are devoted 
to the treatment and imaging of atherosclerotic plaques (for a recent review see ref. [62]). 
Over time, a broad and versatile nanoparticle platform was created in which liposomes and 
biodegradable polymers have turned out to be the most promising candidates. It is 
important to mention that several nanomedicine products have already been established on 
the market and numerous products are successfully applied in clinical trials [63]. However, 
inherent problems of nanoparticles are biocompatibility and low stability in vivo, since most 
nanoparticles become rapidly cleared by the reticuloendothelial system. In contrast to 
artificial systems, lipoproteins are naturally occurring nanoparticles evading recognition by 
the body´s immune system. Hence, lipoproteins are excellent candidates with attractive 
properties to be considered as molecular transporters. A great advantage of LDL over other 
nanoparticles is the fact that LDL particles stay in circulation for several days, and are not 
cleared immediately by the mononuclear phagocyte system of the liver and spleen. The 
average lifetime of an LDL particle is 2-3 days and this time span is about three times longer 
as reported for long-circulating liposomes, currently applied in chemotherapy [64]. It was 
recognized that certain tumor cells overexpress LDL receptor, however, the targeting 
specificity is limited as the LDL receptor is ubiquitously expressed throughout the body, 
most prominent in the liver. However, using apo-B100 as inherent targeting sequence the 
enhanced circulation times in blood enable drug-loaded LDL particles to bind to specific 
receptors exposed on the surface of e.g. tumor or atherosclerotic plaque. Once recognized by 
the receptor, the functionalized LDL particles become internalized, accumulate in the tissue 
and exert an enhanced effect (reviewed by [65]). The intrinsic targeting properties of LDL to 
atherosclerotic plaques are already utilized for early diagnosis and detection of 
atherosclerotic lesions by different imaging modalities (for reviews see refs. [66,67]). 
However, to modify lipoprotein particles for medical purposes, care has to be taken not to 
compromise essential biophysical and structural features of LDL with the goal to preserve 
the biological activity. In general, there are several possibilities to create multi-
functionalized lipoprotein particles. Some representative examples are shown in the scheme 
in Figure 7. One possibility is to load hydrophobic drugs (e.g. chemotherapeutics, 
antibiotics, vitamins, signal emitting molecules or small nanocrystals) in the lipophilic inner 
core of LDL. This can be accomplished by different techniques including lyophilisation, 
solvent evaporation and reconstitution procedures [68,69]. However, LDL particles can not 
be reconstituted so easily and remote drug/contrast agent loading into native lipoprotein 
particles is still a tedious approach currently not being standardized. Amphiphilic 
substances (drugs or marker molecules) or fatty acid modified chelator complexes can be 
incorporated in the PL monolayer [70,71]. This has successfully been done in numerous 
biophysical studies and for diagnostic purposes. Finally, the surface of LDL can be modified 
by protein labeling. This is done by covalent attachment of substances to the lysine and 
cysteine amino acid residues of apo-B100. Such substances include fluorophores, 
radionuclides or metal ions for molecular imaging [65]. Alternatively, targeting sequences 
(e.g. folic acid) can be coupled to apo-B100 with the purpose to reroute LDL to alternate 
receptors, which, in case of folate, are more specifically expressed in tumor cells [72].  
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Figure 6. Scheme giving some examples of how LDL particles can be modified to act as natural 
endogenous nanoparticles for targeted drug delivery or multifunctional molecular imaging. 
To construct lipoprotein mimetic particles, also referred to as lipoprotein related particles, 
artificial lipoprotein particles have to be reassembled from individual lipid and protein 
entities. This approach was highly successful for high density lipoproteins using apo-AI 
mimetic peptide sequences [73]. For LDL, this approach was not pursued yet and will be 
much more complicated considering the complex dynamic nature of apo-B100.  
Over the last few years, a promising nanoparticle platform was established, which exploits 
the endogenous properties of natural lipoproteins being non-toxic, non-immunogenic and 
biodegradable. Although this platform still offers vast potential for improvements, first 
promising results in enhanced multimodal imaging of tumors and atherosclerotic plaques 
are achieved giving hope that further endeavors to combine diagnostics and personalized 
therapeutics will also be successful. 
8. Conclusions and future directions 
The intrinsic flexibility and dynamics of LDL lipids and protein in conjunction with the 
inherent compositional heterogeneity of LDL particles has hitherto hampered successful 
structure determinations at atomic level. Recent technological developments, however, 
allowed to restore characteristic structural features of individual LDL particles at low 
resolution. In particular, using cryo e.m. 3D-reconstruction techniques several groups have 
succeeded in imaging morphological and topological details of LDL to a resolution limit of 
approximately 2 nm [34-36]. Now, new concepts will be needed to make further progress in 
the development of high resolution models of LDL. One promising way is to put stronger 
emphasis on protein crystallography in combination with computational modelling and 
molecular dynamics simulations. X-ray crystallography apprears to be a hopeless pursuit 
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with heterogeneous and flexible particles like LDL. Nevertheless, our earlier attempts of 
crystallisation have been partially successful [74]. Additional efforts, however, have to be 
focussed on the stabilization of apo-B100 in a more rigid state, perhaps by co-crystallisation 
with monoclonal antibodies. An alternative way ahead would be to work with lipid-free 
apo-B100 stabilized by detergent-mimetic systems, e.g. amphipathic designer peptides, or to 
proceed with truncated fragments of apo-B100.  
At present there is still a deficit in our knowledge concerning the molecular lipid trafficking 
mechanisms of LDL. To know the atomic structure of LDL, in particular of apo-B100, may 
well contribute to a better understanding of biologic aspects of cardiovascular diseases, 
especially with respect to future strategies towards rational pharmaceutical interventions. 
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